Intranasal and Inhaled Drug Development Market

Intranasal and Inhaled Drug Development Market by Product Manufacturing Services, Drug Delivery System, Route of Administration, Scale of Operation and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Companies Covered
    223

  • Pages
    223

  • View Count
    16673

Intranasal and Inhaled Drug Development Market Overview

The intranasal and inhaled drug development market is estimated to be worth $5.5 billion in 2020 and is expected to grow at CAGR of 7.6% during the forecast period. Over the past few decades, the prevalence of respiratory disorders has been increasing at an alarming rate. In fact, each year around 7 million deaths are attributed to respiratory disorders caused by air pollution, worldwide.

Moreover, as per a Global Burden of Disease study, around 3 million fatalities are reported annually due to chronic obstructive pulmonary disorders (COPD). It is also important to note that, as of April 2020, an estimated 330 million individuals are suffering from asthma.Other causative factors responsible for respiratory diseases include smoking, climate change, low immunity, inappropriate development of lungs, and bacterial, viral and fungal infections.It is worth mentioning that the novel SARS-CoV2 viral strain is a respiratory pathogen.  

Targeting the delivery of drugs directly into the lungs is deemed to be the most effective way to ensure optimal therapeutic benefits while treating pulmonary disorders. In addition, this route of administration has also been shown to be effective for drugs intended to treat a variety of other conditions, including various metabolic (460+ million adults estimated to be living with diabetes) , hormonal, autoimmune, infectious diseases / disorders and mental health conditions (260 million individuals estimated to be suffering from depression and around 50 million have epilepsy, worldwide). As a result, innovators in the pharmaceutical industry are engaged in efforts to develop the means to formulate and administer pharmacological interventions via inhalation and / or the intranasal route. Since 2019, the FDA has approved multiple inhaled and intranasal drug products, namely TOSYMRA™ (migraine), NUMBRINO™ (local anesthetic), GIMOTI™ (diabetic gastroparesis), VALTOCO® (epilepsy), NAYZILAM® (epilepsy), DUAKLIR® PRESSAIR® (COPD), PROAIR® DIGIHALER™ (asthma and COPD), AIRDUO® DIGIHALER™ (asthma), SPRAVATO® (depression). 

Presently, several players are attempting to develop inhalable versions of different classes of drugs. In such endeavors, reformulating complex therapeutic molecules (such as biologics), novel drug classes (such as nanoparticle based medicine) and those intended for systemic delivery, present unique challenges.Further, the inhaled route of delivery itself has always been associated with several challenges, mostly related to ensuring the drug to its intended target. These concerns are further compounded by multiple physiological barriers, such as mucus hypersecretion / thickening, narrowing / collapse of airways, fibrosis and poor blood circulation. In order to navigate through the aforementioned challenges, innovators prefer to rely on specialty service providers with expertise in inhaled and intranasal nasal medicine. Such players, given their experience and niche expertise, enable innovator companies to not only expedite product development and production timelines, but also offer cost saving opportunities as well. Further, such service providers generally have the necessary infrastructure to scale-up operations in order to meet the evolving needs of a business across different stages of product development. Given the anticipated growth in demand for inhaled and intranasal drug products, the specialty contract services market catering to this segment of the pharmaceutical industry, is anticipated to witness substantial market growth during the forecast period.

This image highlights the context of Inhaled and Intranasal Products report. Inhalable and intranasal variants of drugs / therapies offer a non-invasive approach to dose administration; however, the complexities associated with development and production have caused innovator firms to rely on contract service providers This image provides list of Inhaled and Intranasal Drug Product Service Providers. Presently, more than 110 players, across the globe, claim to provide contract research and manufacturing services to support the development and production of inhaled and intranasal drug products This image presents current market landscape of Inhaled and Intranasal Drug Product Service Providers. The contemporary market features the presence of both seasoned industry veterans and recently established players, offering R&D and production services for inhalable medication and drugs formulated for intranasal dosing

Key Companies in Intranasal and Inhaled Drug Development Market

Examples of key companies engaged in intranasal and inhaled drug development market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Capsugel, Catalent, DPT Laboratories (A Mylan Company), Kindeva Drug Delivery (Formerly 3M Drug Delivery Systems), Beximco Pharmaceuticals, Colep, Hovione, Orion, Quotient Sciences and Recipharm. This market report includes an easily searchable excel database of all the companies providing services for development and manufacturing of intranasal and inhaled drugs, worldwide.

Recent Developments in Intranasal and Inhaled Drug Development Market:

Several recent developments have taken place in the field of intranasal and inhaled drug development market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In May 2023, Strides Pharma Science entered into a strategic collaboration with Orbicular Pharmaceutical Technologies in order to develop, manufacture and commercialize nasal sprays for the global markets. 
  • In March 2023, Pfizer announced the FDA approval of ZAVZPRET™, the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, for the acute treatment of migraine with or without aura in adults. 
  • In March 2023, Stevanato entered into a collaboration with Recipharm with an aim to improve soft mist inhalers.

Scope of the Report

The ‘Intranasal and Inhaled Drug Development Market (Focus on Drugs and Drug Delivery Systems), 2020 – 2030’ market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the intranasal and inhaled drug development market. It features an in-depth analysis, highlighting the capabilities of various contract service providers engaged in intranasal and inhaled drug development market.

This image highlights the geographical distribution of Inhaled and Intranasal Drug Product Service Providers. Several well-established players are steadily expanding their presence across the globe; the US, the UK and India have emerged as hubs for the service providers in this domain This image provides list of Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers. Over time, multiple players with expertise in inhaled and intranasal drugs delivery solutions have emerged, offering a wide range of services to innovator companies across the globe This image highlights competitive analysis of players engaged in the domain of Inhaled and Intranasal Product Services. In order to achieve a competitive edge, companies are putting in significant efforts and capital towards expanding in-house capabilities and thereby, enhancing their respective service portfolios

Amongst other elements, the market research report includes:

  • A detailed assessment of the overall landscape of companies offering contract and custom services for the inhaled and Intranasal drug development and manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, type of service provider (contract manufacturing organization and contract research organization), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (small molecule and biologic), type of inhaled and intranasal related primary service(s) offered (development, manufacturing, analytical testing / services, device selection / optimization and fill / finish and packaging), type of inhaled and intranasal related secondary service(s) offered (process development, pre-formulation development, formulation development, pre-formulation manufacturing, formulation manufacturing, particle engineering, product characterization, extractable and leachable studies, stability testing and plume geometry measurement), type of formulation (powder, aerosol and liquid), type of dosage form (metered dose inhaler, dry powder inhaler, nebulizer, soft mist inhaler, nasal spray, nasal drops, nasal powder and others), route of administration (oral and intranasal inhalation) and installed capacity and batch size (if available).
  • A detailed assessment of the overall landscape of the companies offering contract services for the inhaled and intranasal drug delivery system manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, scale of operation (precommercial and commercial), location of headquarters, location of manufacturing facilities, type of inhaled and intranasal drug delivery system related service(s) offered (design, development, manufacturing, assembly, fill / finish and packaging), type of formulation (powder, aerosol and liquid) and type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer, nasal spray and others).
  • A competitiveness analysis of inhaled and intranasal drug product contract service providers across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration service strength (number of services offered, type of formulation(s) offered and route of administration), manufacturing strength (type of drug molecule, scale of operation, number of manufacturing facilities), supplier strength (company size and its experience in this field) and company size (small-sized, mid-sized and large).
  • Tabulated profiles of some of the key contract manufacturers (shortlisted based on a proprietary criterion) that offer a diverse range of capabilities for the development, manufacturing and packaging of inhaled and intranasal drugs across North America, Europe and Asia-Pacific. Each profile features an overview of the company, along with information related to its financial performance (if available), service portfolio, products and intranasal related capabilities, type of drug molecule, type of dosage form, inhaled and intranasal products related manufacturing facilities, recent developments and an informed future outlook.
  • An analysis of the various partnerships related to inhaled and intranasal contract service providers, which have been established since 2015, based on several parameters, such as year of agreement, type of partnership (development agreements, manufacturing agreements, merger and acquisition, licensing agreement, commercialization, research and development agreements, service alliance, joint venture and other agreements), scale of operation (preclinical, clinical and commercial), type of inhaled and intranasal related service(s) offered (development, manufacturing, analytical testing / services and fill / finish and packaging), type of dosage form (metered dose inhalers, dry powder inhalers, nebulizers and others) and most active players. It also provides the regional distribution of the players involved in the collaborations.
  • A qualitative analysis highlighting the various factors that need to be taken into consideration by inhaled and intranasal product developers, while deciding whether to manufacture their respective products in-house or engage a contract service provider.
  • An estimate of the global, inhaled and intranasal product demand, based on the type of product (inhaled and intranasal), type of drug delivery system used (metered dose inhalers, dry powder inhalers, nebulizers and nasal sprays) and key geographical regions (North America, Europe and Asia-Pacific).
  • An insightful discussion on the impact of COVID-19 outbreak on the inhaled and intranasal service providers. In addition, it features various strategies that different companies have adopted / may adopt in order to mitigate the challenges affiliated to the current global crisis.

The key objective of intranasal and inhaled drug development market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for intranasal and inhaled drug development market during the forecast period. Based on parameters, such as overall pulmonary market, global intranasal drug market, cost of goods sold and outsourcing trends, we have provided an informed estimate of the likely evolution of the contract service providers market in the mid to long term, for the forecast period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] scale of operation (clinical, commercial and both), [B] type of product manufacturing services offered (API manufacturing, end product manufacturing and others), [C] type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer and nasal spray), [D] route of administration (orally inhaled and intranasal) and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition, specific to intranasal service providers, the market has been segmented by the type of drug class (corticosteroids, decongestants, antiallergic, anti-infectives and other topical preparations) and for inhalation service providers, the market has been segmented by the type of disease indication (asthma, COPD, diabetes, cystic fibrosis and others).  In addition to the market forecast for inhaled and intranasal drugs, we have also provided a 10-year forecast for inhaled and intranasal drug delivery systems, covering the market of metered dose inhaler, dry powder inhaler, nebulizer and nasal spray. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

This image highlights the partnership activity undertaken by players engaged in Inhaled and Intranasal Products Services domain. The rising interest in this field is reflected in the number of partnerships inked in the recent past; majority of the deals inked in the given time period were focused on the development of drugs and affiliated devices This image provides information on the current global demand for Inhalation and Nasal Products. The global demand for inhalation and nasal drug delivery systems is expected to increase at a significant pace in the future, with Europe emerging as a key region for this demand This image highlights the market segments of Inhaled and Intranasal Products. The market is projected to be worth over USD 20 billion by 2030; the forecasted opportunity is anticipated to be well distributed across different geographies and drug delivery systems

The opinions and insights presented in this market research report were also influenced by discussions held with senior stakeholders in the industry. The market report features detailed transcripts of interviews held with the following industry and non-industry players:

  • Ben Forbes (Professor, King’s College London)
  • Dries Cardoen (Team Leader of Study Directors, Nelson Laboratories)
  • Neeraj Kumar (Honorary Secretary, The Indian Pharmaceutical Association)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are intranasal and inhaled drugs?

Answer: Intranasal and inhaled drugs include pharmaceutical compositions which are administered via the intranasal route, primarily targeted for the treatment of respiratory disorders.

Question 2: How big is the intranasal and inhaled drug development market?

Answer: The intranasal and inhaled drug development market size is estimated to be worth $5.5 billion in 2020.

Question 3: What is the projected market growth of the intranasal and inhaled drug development market?

Answer: The intranasal and inhaled drug development market is expected to grow at compounded annual growth rate (CAGR) of 7.6% during the forecast period 2020 – 2030.

Question 4: Who are the leading companies in the intranasal and inhaled drug development market?

Answer: Examples of key companies engaged in intranasal and inhaled drug development market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Capsugel, Catalent, DPT Laboratories (A Mylan Company), Kindeva Drug Delivery (Formerly 3M Drug Delivery Systems), Beximco Pharmaceuticals, Colep, Hovione, Orion, Quotient Sciences and Recipharm.

Question 5: How many companies are engaged in the intranasal and inhaled drug development market?

Answer: Presently, over 140 companies are engaged in the intranasal and inhaled drug development market.

Question 6: How many intranasal and inhaled drugs have been approved by the FDA?

Answer: Since 2019, the FDA has approved multiple intranasal and inhaled drugs, namely TOSYMRA™ (migraine), NUMBRINO™ (local anesthetic), GIMOTI™ (diabetic gastroparesis), VALTOCO® (epilepsy), NAYZILAM® (epilepsy), DUAKLIR® PRESSAIR® (COPD), PROAIR® DIGIHALER™ (asthma and COPD), AIRDUO® DIGIHALER™ (asthma), SPRAVATO® (depression).

Question 7: What is the global annual expenditure on the treatment of asthma and COPD?

Answer: Over USD 70 billion is the estimated global annual expenditure on the treatment of asthma and COPD.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com